Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
1.425
-0.075 (-5.00%)
Oct 13, 2026, 12:34 PM EDT - Market open
Equillium Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
90.36M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 41.10M | 5.01M | 13.89% |
| Dec 31, 2023 | 36.08M | 20.33M | 128.97% |
| Dec 31, 2022 | 15.76M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 63.82M |
| ImmuCell | 30.68M |
| Atara Biotherapeutics | 6.19M |
| NeurAxis | 5.32M |
| Rallybio | 646.00K |
| Cardiff Oncology | 508.00K |
EQ News
- 1 day ago - Equillium assumed with an Outperform at Leerink - TheFly
- 6 days ago - Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference - GlobeNewsWire
- 7 days ago - Equillium receives HREC clearance for EQ504 in Australia - TheFly
- 7 days ago - Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 - GlobeNewsWire
- 13 days ago - Equillium Announces Poster Presentations at the 7th International AHR Conference - GlobeNewsWire
- 20 days ago - Equillium Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts
- 27 days ago - Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum - GlobeNewsWire
- 4 weeks ago - Equillium Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts